A major European research effort with Danish participation and EU funding is taking up the battle against aggressive diabetes on a range of fronts.
"With what we know at present, the risk of developing type 2 diabetes appears to lie in changes among our 25,000 genes and to changes in the hundreds of bacteria types living in our gut," says Oluf Borbye Pedersen, Professor of Molecular Metabolism and Genetics at the Novo Nordisk Foundation Centre for Basic Metabolic Research and the Lundbeck Foundation Center for Applied Medical Genomics at the University of Copenhagen.
Professor Oluf Borbye Pedersen has just received a grant of €1.5 million from the EU for an Innovative Medical Initiative to investigate the gut bacteria that are suspected to play a part in the aggressive rapid development of diabetes.
The study will include the monitoring of about 500 Danish subjects who have recently been diagnosed with elevated blood glucose levels.
In addition to the centre at the University of Copenhagen, this major EU partnership also involves a research group from the Technical University of Denmark and nineteen other European universities. To ensure that the research results are turned into preventive tests and new therapies as soon as possible, the EU has entered into a partnership with four pharmaceuticals companies: Sanofi, Servier, Novo Nordisk and Eli Lily.